Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix's GeneStrat Includes ROS1 and RET Mutations

Biodesix has broadened its GeneStrat liquid biopsy test to include ROS1 and RET mutations in addition to EGFR sensitizing, EGFR resistance, KRAS, BRAF, and EML4-ALK alterations.

GeneStrat is a part of the Biodesix's larger "Lung Reflex" multi-omic liquid biopsy testing strategy, which also includes the VeriStrat proteomic testing. With results available within 72 hours, the company says that GeneStrat and VeriStrat together deliver comprehensive information for physicians to support critical treatment decisions at initial diagnosis, expediting appropriate treatment.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.